TNFRSF10B and glioblastoma: In order to validate the above findings in mouse models that mimic the clinical scenario of tumor growth and treatment with surgical resection, we chose a patient derived recurrent primary glioblastoma line, GBM31R (isolated after the first-line resection and treatment with temozolomide) that has low-level surface expression of EGFR and DR4 and high level of DR5 and responds to ENb-TRAIL treatment in a dose dependent manner (Fig. S9A–C).